

Ref.: ADL/SE/2016-17
Date: 10th November, 2016

To,
Department of Corporate Service,
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001.
BSE CODE - 524348

To,
National Stock Exchange of India Limited,
"Exchange Plaza", Bandra - Kurla Complex,
Bandra (E), Mumbai - 400051.
NSE SYMBOL: AARTIDRUGS

Sub: Press Release

Dear Sir/Madam,

Please find enclosed herewith copy of the revised press release issued by the Company on 10th November, 2016.

This is for your kind information and records. Kindly acknowledge the receipt.

Thanking you,

Yours faithfully,
For Aarti Drugs Limited



Vibhav S. Ranade
Company Secretary & Compliance Officer



Encl: A/A

Press release for Sep'16:

September quarter has shown good demand growth both in domestic as well as global markets. Due to lower crude prices, raw material and finished goods prices are lower as compared to previous year. However, excellent volume growth of around 25-30% in the key products, across various geographies, has led to the consolidated sales growth of 15.58%.

Consolidated Profit after tax for the quarter ended Sep'16 is 22.07 crores, up by 40.46% due to higher asset utilization and further reduction in interest cost. Consolidated EBITDA for the quarter ended Sep'16 is 51.14 crores, up by 20.15%. Company was able to keep its net operating working capital to optimum and lowered its Debt/Equity ratio to 1.1

New facility and product approvals for different markets, from the recently expanded capacities, have led to increased sales. Company is expecting an EDQM/European authority audit in 4th week of Nov'16 for the Tarapur facility. Company has invested in automation of its quality systems, which will be helpful for future regulatory audits.

For Aarti Drugs Limited



Harshit M. Savla

Jt. Managing Director

